Bhalla Ashish, Singh Harpreet, Suri Vikas, Yaddanapudi Lakshminarayana, Poddar Banani, Ghawat Ravi, Prabu R Natesh, Sahoo Tapas Kumar, Jose Chacko, Hegde Ashit, Bajan Khusrav, Singh Vinod Kumar, Agarwal Diptimala
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S42-S58. doi: 10.5005/jp-journals-10071-24748. Epub 2024 Aug 10.
Dengue is one of the commonest causes of undifferentiated acute febrile illness in India as well as South East Asia. Nearly two-fifths of the world population is at risk of infection, and nearly 96 million infections reported worldwide, it is a major cause of concern across the globe. The ISCCM leadership felt that there have been no new directives/guidelines except the MOH guidelines for the management of dengue fever since 2014. Under the auspices of the Indian Society of Critical Care Medicine (ISCCM), an expert group of 14 intensivists from across the country, was formed. The task force members formulated questions that needed to be answered. These questions were validated by the members of ISCCM attending research conclave 2023. All the members systematically searched PubMed, MEDLINE, and Science Direct for original articles on different aspects of dengue management between January 1, 2000, and July 1, 2023. From the collected articles, duplicates were removed. Based on the evidence collected, the expert group members prepared statements/answers to the questions. Since most of the evidence is of moderate to low quality, a consensus was generated amongst the members of the task force. Each statement was agreed upon by 70% of the task force. The statements presented in the article are consensus statements as answers to queries raised.
Bhalla A, Singh H, Suri V, Yaddanapudi L, Poddar B, Ghawat R, . ISCCM Position Statement: Management of Severe Dengue in Intensive Care Unit. Indian J Crit Care Med 2024;28(S2):S42-S58.
登革热是印度以及东南亚地区未分化急性发热性疾病最常见的病因之一。全球近五分之二的人口面临感染风险，全球报告的感染病例近9600万例，它是全球主要的关注原因。印度危重症医学学会（ISCCM）的领导层认为，自2014年以来，除了卫生部关于登革热治疗的指南外，没有新的指令/指南。在印度危重症医学学会（ISCCM）的主持下，成立了一个由来自全国各地的14名重症监护专家组成的专家组。特别工作组的成员提出了需要回答的问题。这些问题在参加2023年研究会议的ISCCM成员那里得到了验证。所有成员系统地检索了PubMed、MEDLINE和科学Direct数据库，以查找2000年1月1日至2023年7月1日期间关于登革热治疗不同方面的原始文章。从收集到的文章中，去除了重复的文章。基于收集到的证据，专家组的成员编写了问题的陈述/答案。由于大多数证据的质量为中等至低等，因此在特别工作组的成员之间达成了共识。每项陈述得到了70%的特别工作组成员的认可。本文中提出的陈述是作为对所提问题的答案的共识性陈述。
Bhalla A, Singh H, Suri V, Yaddanapudi L, Poddar B, Ghawat R, 。ISCCM立场声明：重症监护病房中严重登革热的管理。《印度重症监护医学杂志》2024；第28卷（增刊2）：S42 - S58。
